WellSpring Expands Portfolio with DerMend® and Recticare® Following Avista Investment
- WellSpring Consumer Healthcare acquires DerMend® and Recticare® from Ferndale Pharma Group to enhance its skincare portfolio.
- This acquisition is WellSpring's third since receiving investment from Avista Healthcare Partners in August 2022.
- WellSpring aims to solidify its market position and expand its trusted OTC solutions through strategic brand acquisitions.
WellSpring Consumer Healthcare Expands Portfolio with Strategic Acquisition of DerMend® and Recticare®
WellSpring Consumer Healthcare, a prominent player in the over-the-counter (OTC) and personal care market, enhances its leadership in the therapeutic skincare sector through the acquisition of two established brands, DerMend® and Recticare®, from Ferndale Pharma Group. Announced on January 12, 2026, this strategic move aligns with WellSpring's mission to provide high-quality products that meet evolving consumer health needs. DerMend® is renowned for its dermatologist-recommended topical creams designed for aging, fragile, or bruised skin, while Recticare® offers fast relief for hemorrhoids, addressing significant health concerns for many consumers.
This acquisition marks WellSpring’s third add-on since the company received investment from Avista Healthcare Partners in August 2022. Previous acquisitions include A+D® and Solarcaine® from Bayer AG in April 2023, and vH essentials® from Wisconsin Pharmacal Company in July 2024. These strategic decisions reflect WellSpring's commitment to expanding its portfolio and strengthening its market position in therapeutic skincare. CEO Chris Brown underscores the importance of these additions, stating that they significantly enhance the company’s range of trusted OTC and personal care solutions. This focus on acquiring established brands demonstrates WellSpring's strategy to leverage existing consumer trust while addressing a broader spectrum of health and wellness needs.
Founded in 1999 in Sarasota, Florida, WellSpring boasts a diversified portfolio that includes leading names in therapeutic skincare, digestive health, and women's health, such as Bactine® and FDS®. The company operates a sophisticated omni-channel distribution network that encompasses both brick-and-mortar and e-commerce platforms, providing a robust infrastructure for product innovation and market reach. By acquiring DerMend® and Recticare®, WellSpring aims to solidify its competitive edge and continue its growth trajectory in a dynamic market.
In related news, WellSpring's ongoing expansion reflects a broader trend in the healthcare sector, where companies seek to enhance their portfolios through strategic acquisitions. This not only allows them to diversify their offerings but also to tap into new customer segments. The company's commitment to innovation and consumer health remains at the forefront of its strategies, positioning it well for future developments in the OTC market.